[
    [
        {
            "time": "2020-unknown",
            "orginal_text": "《2020年度药品审评报告》解读：药品审评审批“速”“质”提升 全面利好医药行业发展",
            "features": {
                "keywords": [
                    "药品审评",
                    "审批速度",
                    "质量提升",
                    "医药行业"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "《2020年度药品审评报告》解读：药品审评审批“速”“质”提升 全面利好医药行业发展",
            "scores": {
                "News_content": "《2020年度药品审评报告》解读：药品审评审批“速”“质”提升 全面利好医药行业发展",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "unknown",
            "orginal_text": "药明康德参股公司Ambryx在纽交所挂牌上市 已被复兴、厚朴投资收购",
            "features": {
                "keywords": [
                    "药明康德",
                    "Ambryx",
                    "纽交所",
                    "收购"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "药明康德参股公司Ambryx在纽交所挂牌上市 已被复兴、厚朴投资收购",
            "scores": {
                "News_content": "药明康德参股公司Ambryx在纽交所挂牌上市 已被复兴、厚朴投资收购",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "unknown",
            "orginal_text": "2700亿疫苗巨头大跌，一大传闻突袭？黄金坑来了？",
            "features": {
                "keywords": [
                    "疫苗",
                    "大跌",
                    "传闻",
                    "黄金坑"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "2700亿疫苗巨头大跌，一大传闻突袭？黄金坑来了？",
            "scores": {
                "News_content": "2700亿疫苗巨头大跌，一大传闻突袭？黄金坑来了？",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-07-14",
            "orginal_text": "复星医药：7月14日举行2021年第二次临时股东大会",
            "features": {
                "keywords": [
                    "复星医药",
                    "股东大会",
                    "2021"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "复星医药：7月14日举行2021年第二次临时股东大会",
            "scores": {
                "News_content": "复星医药：7月14日举行2021年第二次临时股东大会",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-06-22",
            "orginal_text": "A股资金流向（6月22日）：周期股获资金回流，科技题材龙头遭抛售",
            "features": {
                "keywords": [
                    "A股",
                    "资金流向",
                    "周期股",
                    "科技题材"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "周期股",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "original_text": "A股资金流向（6月22日）：周期股获资金回流，科技题材龙头遭抛售",
            "scores": {
                "News_content": "A股资金流向（6月22日）：周期股获资金回流，科技题材龙头遭抛售",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "unknown",
            "orginal_text": "A股收盘综述：医药龙头午后爆发，采掘、银行全天强势",
            "features": {
                "keywords": [
                    "A股",
                    "医药龙头",
                    "采掘",
                    "银行"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "采掘",
                    "银行"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "A股收盘综述：医药龙头午后爆发，采掘、银行全天强势",
            "scores": {
                "News_content": "A股收盘综述：医药龙头午后爆发，采掘、银行全天强势",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "unknown",
            "orginal_text": "医药生物行业周观点：关注行业政策及上半年业绩超预期的企业",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业政策",
                    "业绩超预期"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "医药生物行业周观点：关注行业政策及上半年业绩超预期的企业",
            "scores": {
                "News_content": "医药生物行业周观点：关注行业政策及上半年业绩超预期的企业",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "unknown",
            "orginal_text": "复星医药AH股齐拉升 研究显示BNT162b2有效率高达93%高于Moderna疫苗",
            "features": {
                "keywords": [
                    "复星医药",
                    "BNT162b2",
                    "有效率",
                    "Moderna"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "复星医药AH股齐拉升 研究显示BNT162b2有效率高达93%高于Moderna疫苗",
            "scores": {
                "News_content": "复星医药AH股齐拉升 研究显示BNT162b2有效率高达93%高于Moderna疫苗",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "unknown",
            "orginal_text": "【异动股】复星医药(02196.HK)涨3.48%",
            "features": {
                "keywords": [
                    "复星医药",
                    "异动股",
                    "涨幅"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【异动股】复星医药(02196.HK)涨3.48%",
            "scores": {
                "News_content": "【异动股】复星医药(02196.HK)涨3.48%",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "unknown",
            "orginal_text": "港股复星医药直线拉升，现涨近6%，报57.85港元，其他抗疫概念股不同程",
            "features": {
                "keywords": [
                    "复星医药",
                    "港股",
                    "拉升",
                    "抗疫概念"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "抗疫"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "港股复星医药直线拉升，现涨近6%，报57.85港元，其他抗疫概念股不同程",
            "scores": {
                "News_content": "港股复星医药直线拉升，现涨近6%，报57.85港元，其他抗疫概念股不同程",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "unknown",
            "orginal_text": "疫苗板块午后转暖，复星医药大涨7%",
            "features": {
                "keywords": [
                    "疫苗",
                    "复星医药",
                    "大涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "疫苗板块午后转暖，复星医药大涨7%",
            "scores": {
                "News_content": "疫苗板块午后转暖，复星医药大涨7%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "unknown",
            "orginal_text": "汉光药业孤儿药获批准上市；勃林格殷格翰精分新药拟纳入突破性治疗；和黄医药索凡替尼获批新适应证",
            "features": {
                "keywords": [
                    "汉光药业",
                    "孤儿药",
                    "勃林格殷格翰",
                    "和黄医药",
                    "索凡替尼"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "汉光药业孤儿药获批准上市；勃林格殷格翰精分新药拟纳入突破性治疗；和黄医药索凡替尼获批新适应证",
            "scores": {
                "News_content": "汉光药业孤儿药获批准上市；勃林格殷格翰精分新药拟纳入突破性治疗；和黄医药索凡替尼获批新适应证",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]